pharma · Recurrent Respiratory Tract Infections · Actinic Keratosis on the Face or Scalp
ALMIRALL S.P.A
Almirall, S.A.
ALMIRALL S.P.A is a pharma organization headquartered in Barcelona, IT. Primary therapeutic focus areas include Recurrent Respiratory Tract Infections, Actinic Keratosis on the Face or Scalp, Alopecia areata, Actinic Ker
VIA MESSINA 38, MILANO, Mi 20154, IT, Barcelona HQ
2 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- VIA MESSINA 38, MILANO, Mi 20154, IT, Barcelona
- Employees
- 2
- Programs
- 11
- Drugs
- 20
- Patents
- 308
Toujeo
Approved · small molecule · Diabetes Mellitus, Type 2
Toujeo for Diabetes Mellitus, Type 2 is a Approved program (small_molecule) at Almirall, S.A. with 1 ClinicalTrials.gov record(s).
Internal code EU-CT number 2022-500449-26-00
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Almirall, S.A.
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Diabetes Mellitus, Type 2
- Status
- completed
- Trials
- 1